3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
63
Lymphoma, Mantle-Cell
39
Waldenstrom Macroglobulinemia
18
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Follicular
14
Recurrence
10
Lymphoma, B-Cell, Marginal Zone
10
Leukemia
9
Lymphoma, B-Cell
8
Lymphoma
8
Neoplasms
7
Lymphoma, Non-Hodgkin
5
Leukemia, Prolymphocytic
4
Hodgkin Disease
4
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Leukemia, B-Cell
3
Hematologic Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Glioblastoma
2
Chromosome 17 deletion
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Bronchiolitis Obliterans Syndrome
2
Brain Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Primary Central Nervous System Lymphoma (PCNSL)
1
Interventions
Temozolomide
64
Radiotherapy
53
Filgrastim
28
Carboplatin
24
Etoposide
20
Irinotecan
17
Vincristine
16
Cyclophosphamide
16
Cisplatin
15
Carmustine
14
Peripheral Blood Stem Cell Transplantation
13
Magnetic Resonance Spectroscopy
12
Bevacizumab
12
Thiotepa
11
Thalidomide
11
Chemotherapy, Adjuvant
11
Methotrexate
10
Paclitaxel
9
Granulocyte Colony-Stimulating Factor
9
etoposide phosphate
8
Surgical Procedures, Operative
8
Procarbazine
8
Ifosfamide
8
sargramostim
7
Topotecan
7
O(6)-benzylguanine
7
Lomustine
7
Busulfan
7
Radiation
6
Melphalan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Central Nervous System Neoplasms
×
ibrutinib
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled